How It Works

The science behind Ember is what makes it the only product of its kind worth paying attention to. Ember’s blend is based on a year of research that paid special attention to the latest scientific breakthroughs and clinical trials. The original blend was formulated by the company’s co-founders, and then perfected by working in direct cooperation with a team of top beverage scientists at a world-renowned flavoring house.

Ember makes hangovers a thing of the past using our unique two-pronged approach. On one hand, Ember counteracts acetaldehyde and aldehyde oxidase, highly toxic byproducts of alcohol that must be broken down in the liver. The problem is that the human liver can only process about a single drink worth of alcohol at a time, so once a person finishes their second drink the toxins are released into the bloodstream where they will become damaging free radicals that are the cause of hangover symptoms. Luckily nature had an answer, and we chose three of the most effective agents available on the market today.

Hangovers are also directly related to the process in which our bodies create and store energy. Normally we create energy by metabolizing carbohydrates, and the human body requires among other things an adequate store of the vitamin B12 for this to happen. Consuming alcohol depletes B12 stores in the body, and carbohydrate metabolism comes to a stop. Your body therefore needs an alternative fuel, and a process known as ketosis begins. When your body enters ketosis the kidneys and liver begin converting fat stores into an alternative energy source. This bodily process is one of the leading reasons social drinkers experience hangover symptoms. Why? Because not only does ketosis place added stress on the liver, but converting fat into energy dehydrates the body extensively.

[1] Norton, Amy. “Milk thistle may limit liver damage from chemo.” Reuters. Available from www.reuters.com. Internet; accessed 4 August 2010.
[1] Borgström, L.; Kågedal, B.; Paulsen, O. (1986). “Pharmacokinetics of N-acetylcysteine in man”. European Journal of Clinical Pharmacology 31 (2): 217–222.